David E Kaplan MD FACP FAASLD AGAF
Hepatology & Liver Transplantation
Professor, Medicine, Perelman School of Medicine
Join to View Full Profile
3400 Civic Center BlvdSte 4-370SPhiladelphia, PA 19104
Phone+1 215-360-0522
Fax+1 215-349-5915
Dr. Kaplan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- David Kaplan, MD, is a gastroenterologist based in Philadelphia, PA, with subspecialties in hepatology and liver transplantation. He completed his residency in internal medicine at Johns Hopkins University and a fellowship in gastroenterology at the University of Pennsylvania Health System. Dr. Kaplan's expertise includes hepatology, viral hepatitides, hepatitis C, non-alcoholic fatty liver disease, and hepatic cirrhosis. He has contributed to several publications, including works on liver cancer models, surgery duration impacts in cirrhosis, and etiological changes in liver disease. His involvement in clinical trials includes studies on statin effects in cirrhosis and delta hepatitis
Education & Training
University of Pennsylvania Health SystemFellowship, Gastroenterology, 2001 - 2004
Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 2000
University of Texas Southwestern Medical SchoolClass of 1997
Certifications & Licensure
DE State Medical License 2024 - 2027
PA State Medical License 2001 - 2026
NJ State Medical License 2003 - 2003
MD State Medical License 1999 - 2002
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Clinical Trials
- Non-Invasive Prediction of Colorectal Neoplasia Start of enrollment: 2006 Aug 01
- Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis Start of enrollment: 2016 Nov 17
Publications & Presentations
PubMed
- Steatotic Liver Disease has Surpassed Viral Hepatitis as the Leading Cause of Cirrhosis in the US Veterans Health System.Pedro Ochoa-Allemant, Akshatha Kiran, Catherine Mezzacappa, David E Kaplan, Nadim Mahmud
The American Journal of Gastroenterology. 2026-07-01 - Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Josep M Llovet, Ezequiel Mauro, Lorenza Rimassa, Vincenzo Mazzaferro, Matthias Pinter
Nature Reviews. Clinical Oncology. 2026-06-10 - Predicting severe liver dysfunction following locoregional therapy for early- and intermediate-stage hepatocellular carcinoma.Jordyn Agins, Catherine Blandon, David E Kaplan, Binu John, Nadim Mahmud
Liver Transplantation. 2026-05-13
Journal Articles
- Racial Disparities in Nephrology Consultation and Disease Progression Among Veterans with CKD: An Observational Cohort StudyMarina Serper, David E Kaplan, Journal of the American Society of Nephrology
Press Mentions
Bariatric Surgery ‘Should Strongly Be Considered’ for Patients with MASH, CirrhosisApril 18th, 2025- Surgery Tops Lifestyle Changes in Patients with CirrhosisApril 9th, 2025
- How to Manage Portal Hypertension and Varices in Cirrhosis: Best PracticesJanuary 13th, 2025
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
